Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment

J. Upham (Brisbane, Australia), D. Jackson (London, United Kingdom), P. Barker (Gaithersburg, United States of America), P. Newbold (Gaithersburg, United States of America), W. Cook (Gaithersburg, United States of America)

Source: International Congress 2019 – Novel findings from asthma clinical trials
Session: Novel findings from asthma clinical trials
Session type: Oral Presentation
Number: 5337

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Upham (Brisbane, Australia), D. Jackson (London, United Kingdom), P. Barker (Gaithersburg, United States of America), P. Newbold (Gaithersburg, United States of America), W. Cook (Gaithersburg, United States of America). Baseline predictors of being exacerbation-free during 2 years of benralizumab treatment. 5337

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: